Imatinib combined with hepatic resection significantly improves overall survival in patients with gastrointestinal stromal tumor liver metastases compared to imatinib monotherapy. Achieving no evidence of disease status through surgical intervention leads to prolonged overall survival, liver-specific progression-free survival, and progression-free survival. Age ≤60 years and combination therapy were independently associated with better outcomes.
Journal Article by Wen H, Huang Y (…) Zhang X et 11 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.